Back to Registry

Body Protection Compound-157

Also known as: BPC-157, PL-14736, Bepecin, PL 10

Research Only

Molecular Formula

C62 H98 N16 O22 Fr Ba

Molecular Weight

1,419.56 Da (Free Base; Acetate salt variable)

Half-Life

~5.3–15.2 minutes (IV in animal models; human PK unestablished)

Sequence

GEPPPGKPADDAGLV (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val)

Clinical Applications & Evidence

Mechanism of Action

In preclinical models, BPC-157 is hypothesized to promote tissue healing via several pathways. In vitro studies demonstrated dissociation of Caveolin-1 from endothelial nitric oxide synthase (eNOS), enhancing nitric oxide production. Preclinical experiments also observed VEGFR2 activation, Akt/eNOS and ERK1/2 pathway modulation, and early transcription factor expression (Egr-1, c-Fos, c-Jun). The exact molecular mechanisms and pharmacological relevance in humans remain unconfirmed.

Investigated Uses

  • Ulcerative colitis & inflammatory bowel conditions (Inconclusive 2005 meeting abstract; unproven in controlled clinical trials)
  • Tendon, ligament & muscle repair (Preclinical animal injury models; no controlled human clinical trials)
  • Wound healing acceleration & angiogenesis (Preclinical rodent models; proposed nitric oxide & VEGFR2 pathways)
  • Neuroprotection & CNS research (Toxin and lesion animal models; unproven in human clinical trials)
Animal Models Only

Regulatory & Safety Status

FDA Status

Research Only

WADA / Athletic Status

Prohibited at All Times (WADA S4.4.1)

Known Side Effects

Human adverse-event frequency and safety profile remain uncharacterized in controlled clinical trialsHeadache and flatulence were reported in small healthy-volunteer enema safety abstractsFDA safety assessment notes potential immunogenicity, aggregation, and impurity risks for compounded injectables

Contraindications

  • WADA-tested athletes (Prohibited at all times under S0 Non-Approved Substances)
  • Active malignancy or history of cancer (Precautionary exclusion due to theoretical angiogenesis concerns)
  • Pregnancy and lactation (Unstudied safety profile)

Drug Interactions

  • Antihypertensives and nitric oxide donors (Theoretical interaction based on preclinical vasodilation studies)
  • Anticoagulants and antiplatelet therapies (Theoretical risk based on preclinical coagulation observations)

Citations & Clinical Trials

FDA FDA Briefing Document: BPC-157 — PCAC Meeting (July 23, 2026) World Anti-Doping Agency WADA 2026 Prohibited List — S0 Non-Approved Substances Guidance Nature Scientific Reports BPC-157 Enhances eNOS Activation via Caveolin-1 Interaction (Sci Rep 2020) PubMed Gastroprotective Pentadecapeptide BPC 157: Novel Therapy in GI Tract (2012) MDPI Pharmaceuticals BPC 157 Characteristics: Structural Analysis and Target Pathways (2025)